Dyadic International To Present At World Biotechnology Congress 2013 And BIO World Congress On Industrial Biotech

 Dyadic International To Present At World Biotechnology Congress 2013 And BIO
                     World Congress On Industrial Biotech

President and CEO, Mark Emalfarb, to Provide Update on Dyadic's C1 Enzyme
Technology and Progress Towards Producing Cellulosic Sugars for Fuels and
Chemicals

PR Newswire

JUPITER, Fla., May 29, 2013

JUPITER, Fla., May 29, 2013 /PRNewswire/ --Dyadic International, Inc.
("Dyadic") (OTC Pink: DYAI), announced today that its President and CEO, Mark
Emalfarb, will present at the World Biotechnology Congress 2013 in Boston,
Massachusetts and the BIO World Congress on Industrial Biotech in Montreal,
Canada.

(Logo: http://photos.prnewswire.com/prnh/20110621/CL06708LOGO )

Dyadic is a global biotechnology company focused on the discovery,
development, manufacture and sale of enzymes and other proteins for the
bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme
industries.

Emalfarb's presentation at the World Biotechnology Congress will take place on
June 6th, from 11:20 – 11:40 a.m. EDT, in Lecture Hall No. 201 (Level 2) at
the John B. Hynes Veterans Memorial Convention Center.

Titled "Dyadic's C1 Enzyme Technology Update: On the Road to Cellulosic Sugars
for Fuels and Chemicals," Emalfarb will discuss Dyadic's license agreements,
commercial developments and progress toward producing cost-competitive
cellulosic biofuels from agricultural byproducts such as corn stover and wheat
straw.

Emalfarb will also co-chair the Industrial and Manufacturing session scheduled
for Thursday, June 6th, from 2:00 – 5:10 p.m. EDT in Lecture Hall No. 201.
The session will feature presentations on next-generation biofuels and new
routes toward the development of novel antifungal therapeutics, among others.

At the BIO World Congress on Industrial Biotech on June 18th, Emalfarb will
participate on a panel called "Global Benefits for Synthetic Biology Tools"
from 10:30 a.m. – 12:00 p.m. EDT at the Palais des Congres de Montreal.

"Dyadic is making significant progress towards producing economically viable
cellulosic biofuels and chemicals from C1-derived enzymes," said Emalfarb.
"For instance, we expect that our C1 platform will be used to produce enzymes
in commercial volumes when Abengoa Energy starts up its commercial scale
cellulosic ethanol biorefinery in Hugoton, Kansas later this year."

Emalfarb continued, "We look forward to providing an update on this and other
commercial developments at both of these internationally recognized scientific
conferences."

About World Biotechnology Congress 2013

The World Biotechnology Congress 2013 will focus on various important
disciplines of biotechnology and its applications for improvement in health
and quality of life the world over. It is anticipated that up to 1000 of the
world's leading scientists, researchers, industrialists and academicians,
including several Nobel Laureates, in the fields of biotechnology as well as
medical and biological sciences, will attend this forum in Boston, to share
and discuss new scientific ideas, products and breakthroughs.

About BIO World Congress

The BIO World Congress on Industrial Biotechnologyis the world's largest
industrial biotechnology event for business leaders, investors, and policy
makers in biofuels, bio-based products, and renewable chemicals.

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its
patented and proprietary technologies to conduct research, development and
commercial activities for the discovery, development, manufacture and sale of
enzyme and protein products for the bioenergy, industrial enzyme and
biopharmaceutical industries. Dyadic utilizes an integrated technology
platform based on its patented and proprietary C1 fungus which enables the
development and large scale manufacture of low cost proteins and enzymes for
diverse market opportunities. The C1 platform technology can also be used to
screen for the discovery of novel genes and proteins. Dyadic actively pursues
licensing arrangements and other commercial opportunities to leverage the
value of these technologies by providing its partners and collaborators with
the benefits of manufacturing and/or utilizing the enzymes which these
technologies help produce. Please visit Dyadic's website at www.dyadic.com.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking
statements. These forward-looking statements involve risks and uncertainties
that could cause Dyadic's actual results, performance or achievements to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Except as required by
law, Dyadic expressly disclaims any intent or obligation to update any
forward-looking statements.

SOURCE Dyadic International, Inc.

Website: http://www.dyadic.com
Contact: For Dyadic: Investor Relations: Gary T. Dvorchak, CFA, Senior Vice
President, ICR, Inc., 310-954-1123, Gary.Dvorchak@icrinc.com, or Media
Relations: Cory Ziskind, Vice President, ICR, Inc., 646-277-1232,
Cory.Ziskind@icrinc.com
 
Press spacebar to pause and continue. Press esc to stop.